Navigation Links
Horizon Therapeutics Names Timothy P. Walbert as President and CEO
Date:7/24/2008

PALO ALTO, Calif., July 24 /PRNewswire/ -- Horizon Therapeutics, Inc., a privately held biopharmaceutical company, today announced that Timothy P. Walbert has been named president, chief executive officer and member of the board of directors of Horizon Therapeutics.

"Tim has a long, proven track record of successfully commercializing multi-billion dollar drugs in the pain and arthritis areas," said George Tidmarsh, M.D., Ph.D., founder, scientific consultant and board member of Horizon. "Tim has the perfect background to lead our company as we move toward the unblinding of the Phase 3 clinical data for our lead product candidate HZT-501, a proprietary formulation of ibuprofen combined with famotidine in a single pill. We are thrilled to have someone of his caliber joining Horizon."

Mr. Walbert has nearly two decades of executive, general management, marketing and sales experience in the pharmaceutical and biotech industries. Mr. Walbert is currently president and chief executive officer of IDM Pharma (Nasdaq: IDMI), a biopharmaceutical company focused on the development of innovative products that activate the immune system to treat cancer. Prior to IDM Pharma, Mr. Walbert served as executive vice president, commercial operations at NeoPharm, Inc.

Mr. Walbert previously was at Abbott where he served as divisional vice president and general manager of Abbott Immunology and divisional vice president of global cardiovascular marketing. Under his leadership, he was responsible for the creation of Abbott Immunology through the approval, launch and commercialization of HUMIRA(R) for the treatment of rheumatoid arthritis in the United States, Europe and other countries. HUMIRA became the most successful launch in Abbott's history, achieving sales of more than $1.4 billion by 2005 and is expected to exceed $3 billion in 2008.

Mr. Walbert also served as director, Celebrex(R) North America and arthritis team leader, Asia Pacific, Latin America and Canada at Searle/Pharmacia. He coordinated Celebrex activities in Canada, Australia, and Latin America where aggregate sales grew to nearly $400 million in 2000, making it one of the most successful pharmaceutical products launched in many of those countries. Mr. Walbert also held a number of other key marketing and sales positions with Searle/Pharmacia, which included the U.S. launch of Arthrotec(R), a combination arthritis/pain product which generated more than $200 million in first year sales in 1998 and Daypro(R), an arthritis/pain product which generated more than $300 million in peak U.S. sales.

"I am excited by the opportunity to lead Horizon and help bring a new therapeutic option to market that may offer patients effective pain relief with GI-protection," said Mr. Walbert. "Approximately 25 percent of regular NSAID users may develop stomach ulcers and there continues to be a significant unmet treatment need for effective pain relief while lowering a patient's risk of developing these ulcers. Horizon is well positioned to address this need and become a market leader."

About Horizon Therapeutics

Horizon Therapeutics, Inc. is a late-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of mild-to-moderate pain and arthritis. Horizon's clinical portfolio includes innovative combination therapies in early- and late-stage development that are designed to improve safety, efficacy, and patient compliance. For more information about the company and its products, please visit http://www.horizontherapeutics.com.


'/>"/>
SOURCE Horizon Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. RxPop.com Wins 7th Annual Horizon Interactive Award
2. New possibilities for breast cancer treatment on the horizon
3. Thomson Reuters Adds Routes of Synthesis Data to Its Newport Horizon Premium and Newport Vision Premium Solutions
4. Osteotech Engages BioHorizons as Exclusive Distributor to International Dental Market
5. Hill-Rom Selects NanoHorizons to Provide Antimicrobial Protection for Hill-Rom Products Using Nanotechnology
6. Horizon Organic(R) Family Farmer Network Grows by Nearly 35 Percent
7. BioHorizons Expands to New 44,000 Square Foot Facility
8. BioHorizons Introduces Its New Tapered Internal Implants Featuring Laser-Lok(R) Microgrooves
9. NetSuite Partners Introduce New Vertical Versions of NetSuite and Horizontal Extensions to Core NetSuite Functionality
10. Targets on the horizon: Emerging therapies and novel targets
11. HORIZONS AMI trial data will help set guidelines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun ... NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is ... is geared towards children of all ages; it is a non-competitive, non-timed event, which ...
(Date:10/13/2017)... ... , ... “The Journey: From the Mountains to the Mission Field”: the story ... the Philippines. “The Journey: From the Mountains to the Mission Field” is the creation ... has taught all ages and currently teaches a class of ladies at her church, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the largest and fastest ... to open a flagship location in Covington, LA at 401 N. U.S. Highway 190, ... next to Office Depot in the Holiday Square shopping center. Its location allows it ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... in post-acute health care, have expanded their existing home health joint venture through ... AccentCare has been operating a joint venture home health company with Asante, delivering ...
(Date:10/12/2017)... ... 2017 , ... Leading pediatric oncology experts at Children’s National Health System ... Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of ...
Breaking Medicine News(10 mins):
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, Inc. ... response letter from the U.S. Food and Drug Administration ... of sirukumab for the treatment of moderately to severely ... additional clinical data are needed to further evaluate the ... severely active RA. ...
(Date:9/19/2017)... LOUISVILLE, Ky. , Sept. 19, 2017   ZirMed ... and predictive analytics, today announced that it has been ranked ... the Black Book™ Rankings 2017 User Survey. ZirMed ... software solution for large hospitals and medical centers over 200 ... in Black Book,s healthcare technology user survey history. ...
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017   ... for global supply chains, has published the first annual edition of its ... of more than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings ... 2016. ... CSR Risk & Performance Index ...
Breaking Medicine Technology: